New Zealand markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
48.74-0.10 (-0.20%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close48.84
Open48.26
BidN/A x N/A
AskN/A x N/A
Day's range48.00 - 48.79
52-week range39.72 - 51.05
Volume1,020,097
Avg. volume1,015,185
Market cap337.425B
Beta (5Y monthly)0.29
PE ratio (TTM)22.04
EPS (TTM)2.21
Earnings dateN/A
Forward dividend & yield1.22 (2.50%)
Ex-dividend date18 Mar 2021
1y target est56.44
  • Motley Fool

    Why Atea Pharmaceuticals Stock Got Crushed This Week

    Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).

  • GlobeNewswire

    FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

    Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy continuously delivering medicine into the eye through a refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per yearNeovascular AMD impacts approximately 20 million people worldwide and is a leading cause of blindness in people over the age of 6

  • Business Wire

    FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)

    SOUTH SAN FRANCISCO, Calif., October 22, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a potentially